WO2010151080A3 - 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 - Google Patents

카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 Download PDF

Info

Publication number
WO2010151080A3
WO2010151080A3 PCT/KR2010/004152 KR2010004152W WO2010151080A3 WO 2010151080 A3 WO2010151080 A3 WO 2010151080A3 KR 2010004152 W KR2010004152 W KR 2010004152W WO 2010151080 A3 WO2010151080 A3 WO 2010151080A3
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylosartan
pharmaceutical composition
production method
composition containing
method therefor
Prior art date
Application number
PCT/KR2010/004152
Other languages
English (en)
French (fr)
Other versions
WO2010151080A2 (ko
Inventor
최재준
장성백
전홍렬
이봉상
김현일
Original Assignee
진양제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 진양제약 주식회사 filed Critical 진양제약 주식회사
Priority to EP10792362.5A priority Critical patent/EP2446879B1/en
Priority to US13/380,266 priority patent/US20120095067A1/en
Priority to CN201080028788.7A priority patent/CN102802611B/zh
Priority to KR1020117030206A priority patent/KR101817986B1/ko
Priority to JP2012517397A priority patent/JP5442116B2/ja
Publication of WO2010151080A2 publication Critical patent/WO2010151080A2/ko
Publication of WO2010151080A3 publication Critical patent/WO2010151080A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법에 관한 것이다. 본 발명은 용출률 및 용출속도가 향상되고, 매질 pH에 따른 용출편차가 감소한 카르복시로자탄 함유 약학 조성물 및 이의 제조방법을 제공한다.
PCT/KR2010/004152 2009-06-25 2010-06-25 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 WO2010151080A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10792362.5A EP2446879B1 (en) 2009-06-25 2010-06-25 Pharmaceutical composition containing carboxylosartan and a production method therefor
US13/380,266 US20120095067A1 (en) 2009-06-25 2010-06-25 Pharmaceutical composition containing carboxylosartan and a production method therefor
CN201080028788.7A CN102802611B (zh) 2009-06-25 2010-06-25 含氯沙坦羧酸的药物组合物及其生产方法
KR1020117030206A KR101817986B1 (ko) 2009-06-25 2010-06-25 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법
JP2012517397A JP5442116B2 (ja) 2009-06-25 2010-06-25 ロサルタンカルボン酸を含有する薬学組成物及びその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0057054 2009-06-25
KR20090057054 2009-06-25

Publications (2)

Publication Number Publication Date
WO2010151080A2 WO2010151080A2 (ko) 2010-12-29
WO2010151080A3 true WO2010151080A3 (ko) 2011-05-19

Family

ID=43387070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/004152 WO2010151080A2 (ko) 2009-06-25 2010-06-25 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법

Country Status (6)

Country Link
US (1) US20120095067A1 (ko)
EP (1) EP2446879B1 (ko)
JP (1) JP5442116B2 (ko)
KR (1) KR101817986B1 (ko)
CN (1) CN102802611B (ko)
WO (1) WO2010151080A2 (ko)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043210A1 (en) * 1998-02-25 1999-09-02 Merck & Co., Inc. Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
US20030104053A1 (en) * 2001-10-25 2003-06-05 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20060229350A1 (en) * 2005-04-01 2006-10-12 Gianpiero Ventimiglia Losartan potassium crystalline form alpha
US20080096866A1 (en) * 2004-12-30 2008-04-24 Hanmi Pharm. Co., Ltd. Complex Formulation Of 3-Hydroxy-3-Methyl Glutaryl Coa Reductace Inhibitor And Antihypertensive Agent, And Process For Preparing Same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021436A1 (en) * 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan
JP2008536929A (ja) * 2005-04-18 2008-09-11 ルビコン・リサーチ・ピーヴィーティー・エルティーディー 生体強化組成物
WO2006115834A1 (en) * 2005-04-20 2006-11-02 Merck & Co., Inc. Angiotensin ii receptor antagonists
JP4965096B2 (ja) * 2005-08-19 2012-07-04 テバ製薬株式会社 圧縮成型製剤
TW200734304A (en) * 2005-11-08 2007-09-16 Astellas Pharma Inc Benzene derivative or salt thereof
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US20100008956A1 (en) * 2008-07-08 2010-01-14 Jie Du Composition and combinations of carboxylic acid losartan in dosage forms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043210A1 (en) * 1998-02-25 1999-09-02 Merck & Co., Inc. Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
US20030104053A1 (en) * 2001-10-25 2003-06-05 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20080096866A1 (en) * 2004-12-30 2008-04-24 Hanmi Pharm. Co., Ltd. Complex Formulation Of 3-Hydroxy-3-Methyl Glutaryl Coa Reductace Inhibitor And Antihypertensive Agent, And Process For Preparing Same
US20060229350A1 (en) * 2005-04-01 2006-10-12 Gianpiero Ventimiglia Losartan potassium crystalline form alpha

Also Published As

Publication number Publication date
EP2446879A2 (en) 2012-05-02
US20120095067A1 (en) 2012-04-19
EP2446879A4 (en) 2012-11-21
KR20120111935A (ko) 2012-10-11
JP5442116B2 (ja) 2014-03-12
EP2446879B1 (en) 2014-02-12
CN102802611A (zh) 2012-11-28
WO2010151080A2 (ko) 2010-12-29
CN102802611B (zh) 2014-11-12
JP2012530778A (ja) 2012-12-06
KR101817986B1 (ko) 2018-01-16

Similar Documents

Publication Publication Date Title
WO2007093627A3 (de) Biozide zusammensetzung
EP2380995A4 (en) Smelting vessel, steel making plant and steel production method
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
EP2474539A4 (en) DIEPOXY COMPOUND, PREPARATION METHOD AND COMPOSITION WITH THE DIEXOXY COMPOUND
EP2334800A4 (en) MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL
WO2009149956A3 (en) Fusion protein and use thereof
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010110599A3 (ko) 신규한 알파-네오 아가로바이오스 가수분해 효소 및 그를 이용한 단당류의 획득 방법
WO2010078900A3 (de) Neue aliphatisch substituierte pyrazolopyridine und ihre verwendung
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
IL213324A (en) Beverages and barley plant compositions, and methods for making barley beverages or compositions
EP2407546A4 (en) REDUCING MIXTURE DERIVED FROM MICROORGANISMS WITH OXYDO-REDUCTION POTENTIAL LESS THAN OR EQUAL TO 0 MV, AND PROCESS FOR PRODUCING THE SAME
WO2012136898A3 (en) Novel cutinases, their production and uses
EG25112A (en) Dual subsea production chokes for high pressure well production.
WO2010136104A3 (en) Anti-dandruff agents
WO2008023264A3 (en) Coenzyme q10 production from marine bacteria
WO2011051465A3 (de) Verfahren zur herstellung von metallverbindungen
HK1184823A1 (en) Novel soil microorganism, novel oxidoreductase separated from the soil microorganism, gene encoding the oxidoreductase, and method for producing aglycones using the microorganism, the oxidoreductase and the gene
EP2336312A4 (en) TRITERPENOXIDASE DERIVED FROM THE GLYCHYRRHIZA PLANT, THE OXIDASE-CODING GENE AND METHOD OF USE OF THE GENE
WO2010098583A2 (ko) 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
WO2010053950A3 (en) Biosynthesis of styrene and 7-methyl-1,3,5-cyclooctatriene
EP2141229A4 (en) PULVERULENT PREPARATION OF LIPASE, PROCESS FOR PRODUCTION THEREOF AND USE THEREOF
WO2011067236A3 (de) Raltegravir-polymorphe
MX285136B (es) Metodo de produccion de polieteramina.
EP2634183B8 (en) Method for preparing 1,3,5-trioxane

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080028788.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792362

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20117030206

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012517397

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13380266

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010792362

Country of ref document: EP